GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae
BANGALORE, INDIA / SINGAPORE - Media OutReach Newswire - 23 December 2024 - GangaGen announced…